01 / EvidenceSelected study results
MariTide Phase 2 · weight management without type 2 diabetesMean body-weight reductionBody weight decreased 16.2% · 52 weeks · Phase 2
Phase 2 · Injection · Peer-reviewed resultsMean body-weight reduction · 52 weeks
Study focus: Weight management without type 2 diabetes
Investigational regimen
16.2% Adults with obesity or overweight without type 2 diabetes · Highest-dose monthly regimen vs placebo · Trial N=465 · Treatment-policy estimand; highest-dose group. This is the main result shown for this study.. Results & methods ↗ · Publication ↗
Additional results or analyses from this same study- Same cohort · efficacy estimandAt the same highest monthly dose, the efficacy-estimand estimate was 19.9% mean weight reduction versus 2.6% with placebo at 52 weeks.
- Type 2 diabetes cohort · treatment-policy estimandIn the separate type 2 diabetes cohort of this same Phase 2 study, mean weight reduction was 12.3% versus 1.7% with placebo at the highest monthly dose at 52 weeks.
- Part 2 · maintenance follow-upThe sponsor reported that most selected participants who had lost at least 15% in Part 1 maintained that loss during a further 52 weeks on lower monthly or quarterly regimens. This was an exploratory extension. Follow-up source ↗
One Phase 2 study (NCT05669599) included separate cohorts with and without type 2 diabetes; the two additional values below are within-study analyses, not separate trials.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Sponsor announcementsFindings awaiting numerical detail
Dedicated MariTide Phase 2 diabetes study
Numerical results not disclosed in the cited update · 24 weeks · Phase 2
Amgen announced reductions in HbA1c and body weight at 24 weeks.
The cited sponsor announcement does not disclose arm-level numerical values or estimand details. A numerical comparison cannot be shown. This dedicated diabetes study is separate from the published 52-week obesity study above.
Sponsor announcement ↗02 / How it worksMechanism at a glance
GLP-1GLP-1Receptor agonist
GIPGIPReceptor antagonist
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗03 / DevelopmentObesity stage by formulation
Milestone → nextLatest: Amgen’s November 3, 2026 update reports completed enrollment in MARITIME-CV, both OSA studies and the Phase 2b liver-fat study; MARITIME-T2D-3 has initiated. These enrollment milestones are not study completion or new efficacy results.
Next: MARITIME obesity and related-condition outcomes. Two additional Phase 3 type 2 diabetes studies remain planned for Q4 2026.
04 / Study recordsClinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies6 records
Phase 3MARITIME-1
Weight management without type 2 diabetesStudy: OngoingResults: No registry results posted yetStatus reviewed November 2026
Chronic weight management in adults with obesity or overweight without type 2 diabetes; ongoing per Amgen Q2 2026 update.
Phase 3MARITIME-1 EXTENSION
Weight-loss maintenanceStudy: OngoingResults: No registry results posted yetStatus reviewed November 2026
Long-term maintenance in eligible MARITIME-1 completers without type 2 diabetes; monthly, every-eight-week or quarterly regimens. Enrolling per Amgen’s November 3 update.
Phase 3MARITIME-2
Weight management with type 2 diabetesStudy: OngoingResults: No registry results posted yetStatus reviewed November 2026
Chronic weight management in adults with obesity or overweight with type 2 diabetes; ongoing per Amgen Q2 2026 update.
Phase 3MARITIME-2 EXTENSION
Weight-loss maintenance with type 2 diabetesStudy: OngoingResults: No registry results posted yetStatus reviewed November 2026
Long-term maintenance in eligible MARITIME-2 completers with type 2 diabetes; monthly or every-eight-week regimens. Enrolling per Amgen’s November 3 update.
Phase 3MARITIME-SWITCH
Weight maintenance / switchingStudy: OngoingResults: No registry results posted yetStatus reviewed November 2026
Evaluates switching adults with overweight or obesity from weekly semaglutide or tirzepatide to MariTide; enrolling per Amgen November 3, 2026 update.
Phase 3 plannedAdditional type 2 diabetes program
Weight management with type 2 diabetesStudy: PlannedResults: No results reported; study plannedStatus reviewed September 2026
Amgen said three Phase 3 MariTide studies in people with type 2 diabetes were planned to initiate in 2026; individual study registrations and current initiation status were not matched in this review.
Phase 2 studies1 record
Phase 2Phase 2 obesity study
Weight managementStudy: CompletedResults: Peer-reviewed results shown aboveStatus reviewed November 2026
One 52-week dose-ranging study with separate cohorts with and without type 2 diabetes; treatment-policy estimate is the main result, with the efficacy estimand shown as a within-study note.
Related conditions and outcomes
Phase 3 studies5 records
Phase 3MARITIME-CV
Cardiovascular outcomesStudy: OngoingResults: No registry results posted yetStatus reviewed November 2026
Cardiovascular outcomes in adults with established atherosclerotic cardiovascular disease and overweight or obesity. Amgen’s November 3, 2026 update reports enrollment complete; results remain pending.
Phase 3MARITIME-HF
Heart-failure outcomesStudy: OngoingResults: No registry results posted yetStatus reviewed November 2026
Mortality, morbidity, and symptoms in adults with HFpEF or HFmrEF and obesity; enrolling per Amgen November 3, 2026 update.
Phase 3MARITIME-OSA-1
Sleep-apnea outcomesStudy: OngoingResults: No registry results posted yetStatus reviewed November 2026
Obstructive sleep apnea in adults on positive airway pressure therapy with overweight or obesity. Amgen’s November 3, 2026 update reports enrollment complete; results remain pending.
Phase 3MARITIME-OSA-2
Sleep-apnea outcomesStudy: OngoingResults: No registry results posted yetStatus reviewed November 2026
Obstructive sleep apnea in adults not on positive airway pressure therapy with overweight or obesity. Amgen’s November 3, 2026 update reports enrollment complete; results remain pending.
Phase 3MARITIME-T2D-3
Glycemic control in type 2 diabetesStudy: Initiated / enrolling per sponsor; registry not yet recruitingResults: No registry results posted yetStatus reviewed November 2026
Estimated 1,300 adults with type 2 diabetes; open-label monthly MariTide versus weekly semaglutide, primary HbA1c noninferiority at week 68. Sponsor reports initiation/enrollment November 3; the October 8 registry snapshot remains not yet recruiting.
Phase 2 studies2 records
Phase 2bElevated liver fat and weight-loss study
Liver outcomes (MASLD / MASH)Study: OngoingResults: No registry results posted yetStatus reviewed November 2026
Adults with elevated liver fat and overweight or obesity. Amgen’s November 3, 2026 update reports enrollment complete; results remain pending.
Phase 2Phase 2 type 2 diabetes study
Glycemic control in type 2 diabetesStudy: OngoingResults: No registry results posted yetStatus reviewed November 2026
Dedicated glycemic-control study in adults with type 2 diabetes, with and without obesity; 24-week findings were presented by Amgen in January 2026.